Hao Fu
- Cancer Research top 5%
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 10
- Oncology top 5%
- Cancer-related Molecular Pathways 11
- Peptidase Inhibition and Analysis 11
- Biomedical Engineering top 5%
- Nanoplatforms for cancer theranostics 25
- Molecular Biology top 10%
- Advanced biosensing and bioanalysis techniques 8
-
- Radiopharmaceutical Chemistry and Applications 14
-
- Thyroid Cancer Diagnosis and Treatment 11
-
- Catalytic Processes in Materials Science 8
- Co-authors
- Yaping DuYourong DuanYong JiangZhong LiangHaojun ChenChuanrong ChenChunlei ZhuJianlin Shi
- Cited by
- Cancer ResearchBiomaterialsOncology
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Hao Fu
151 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Cancer Research 437
- Biomaterials 375
- Oncology 738
- Biomedical Engineering 794
- Molecular Biology 1.0k
Countries citing papers authored by Hao Fu
This map shows the geographic impact of Hao Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Fu more than expected).
Fields of papers citing papers by Hao Fu
This network shows the impact of papers produced by Hao Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Fu. The network helps show where Hao Fu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hao Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 4 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 0 | |
| 6 | 2025 | 13 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 7 | |
| 9 | 2024 | 12 | |
| 10 | 2024 | 9 | |
| 11 | 2024 | 8 | |
| 12 | 2023 | 11 | |
| 13 | 2023 | 56 | |
| 14 | 2023 | 18 | |
| 15 | 2023 | 97 | |
| 16 | 2022 | 59 | |
| 17 | 2022 | 4 | |
| 18 | 2021 | 61 | |
| 19 | 2021 | 19 | |
| 20 | 2018 | 0 |
About Hao Fu
Hao Fu is a scholar working on Cancer Research, Oncology and Endocrinology, Diabetes and Metabolism, having authored 164 papers that have together received 3.3k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (25 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Cancer-related Molecular Pathways (11 papers), Thyroid Cancer Diagnosis and Treatment (11 papers), Peptidase Inhibition and Analysis (11 papers), Nanoparticle-Based Drug Delivery (10 papers), Catalytic Processes in Materials Science (8 papers) and Advanced biosensing and bioanalysis techniques (8 papers). The work is most often cited by research in Cancer Research (437 citations), Biomaterials (375 citations) and Oncology (738 citations). Hao Fu has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Yaping Du, Yourong Duan, Yong Jiang, Zhong Liang, Haojun Chen, Chuanrong Chen, Chunlei Zhu, Jianlin Shi, Minghui Xiao and Linqi Shi. Their work appears in journals such as BMC Cancer, ACS Nano, Advanced Science, Biomaterials and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.